Decheng Capital is a leading China venture capital firm that provides capital to early and growth stage life science companies. We are a team of investment professionals with complementary expertise, a long history of working together and a shared dedication to building highly successful companies that span the full spectrum of the life sciences industry. Our domain knowledge, access to innovative technologies and ability to bring proven Western products to China make us the preferred partner for entrepreneurs, domestic and multinational companies, government agencies and investors. Decheng Capital is poised to capitalize on a historic opportunity in China's rapidly developing life sciences industry and to deliver superior returns for our investors.
52
Total Investments
36
Portfolio Companies
-
Exits
2
Industries
General Information
Industries
Financial Services, Health Care
Company Overview
Investment Criteria
Investment Thesis
•••••• •••••• ••••••
About Decheng Capital
Recent Investments (52)
View All| Company | Stage | Amount | Date |
|---|---|---|---|
| Series D | •••••• | Jan 2026 | |
| Series A | •••••• | Feb 2024 | |
| Series E | •••••• | Jan 2024 | |
| Series A | •••••• | Nov 2023 | |
| Series B | •••••• | Sep 2023 | |
|
|
Series F | •••••• | Aug 2023 |
|
|
Early VC | •••••• | Aug 2023 |
|
|
Series C | •••••• | Aug 2023 |
|
|
Series B | •••••• | Jun 2023 |
|
|
Venture Round | •••••• | Apr 2023 |
All startup & investor data, one platform.
Filter investors by stage, sector, and geography. Compare portfolios side by side. Spot market signals before anyone else.